Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 27, Issue 10, 2014, Pages 1038-1048

  Moore Simas, Tiffany A ^a   Crawford, Sybil L ^a   Bathgate, Susanne ^b   Yan, Jing ^a   Robidoux, Laura ^c   Moore, Melissa ^a   Maynard, Sharon E ^b,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Department of Medicine Division of Preventive and Behavioral Medicine University of Massachusetts Medical School ^*  (United States)

^d LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

Angiogenic factors; Placenta growth factor (PlGF); Preeclampsia; Soluble endoglin (sEng); Soluble fms like tyrosine kinase 1 (sFlt1)

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE ENDOGLIN; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREDICTION; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ADULT; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREGNANCY; RISK FACTOR; SECOND TRIMESTER PREGNANCY; STATISTICAL MODEL; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DECISION SUPPORT TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84902145028     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.847415     Document Type: Article

References (53)

1. Anonymous. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
2. ACOG. ACOG practice bulletin (No. 33)-diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002, reaffirmed 2010;99:159-67.
3. Turner JA. Diagnosis and management of pre-eclampsia: an update. Int J Women's Health 2010;2:327-37.
4. Saftlas AF, Olason DR, Franks AL, et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990;163:460-65.
5. Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. Br Med J 2005; 330:565.
6. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. J Am Med Assoc 1991;266:237-41.
7. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 2003;111:649-58.
8. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award. Am J Obstet Gynecol 2004;190: 1541-50.
9. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12: 642-9.
10. Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007;197:244.e1-8.
11. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004;350: 672-83.
12. Levine RJ, Lam C, Qian C. Soluble endoglin and other circuliating antiangiogenic factors in preeclampsia. New Engl J Med 2006;355: 992-1005.
13. Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137-72.
14. Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007;197:174e1-5.
15. Maynard SE, Moore Simas TA, Bur L, et al. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertens Pregn 2010;29:330-41.
16. Maynard SE, Moore Simas TA, Solitro MJ, et al. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198:200.e1-7.
17. ACOG. ACOG Practice Bulletin (No. 101): ultrasonography in pregnancy. Obstet Gynecol 2009;113:451-61.
18. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
19. Cleveland WS. Visualizing data. Summit, NJ: Hobart Press; 1993.
20. Bassett GW, Koenker R. An empirical quantile function for linear models with iid errors. J Am Stat Assoc 1982;77:401-15.
21. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New York: Wiley; 2004.
22. Qin G, Hotilovac L. Comparison of non-parametric confidence intervals for the area under the ROC curve of a continuous-scale diagnostic test. Stat Methods Med Res 2008;17:207-21.
23. Le CT. A solution for the most basic optimization problem associated with an ROC curve. Stat Methods Med Res 2006;15: 571-84.
24. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-Angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021-38.
25. Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-74.
26. Sibai BM, Koch MA, Freire S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008;199:268 e1-9.
27. Levine RJ, Qian C, Maynard SE, et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstetr Gynecol 2006;194:1034-41.
28. Myatt L, Clifton RG, Roberts JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstetr Gynecol 2012;119:1234-42.
29. Rohra DK, Zeb A, Qureishi RN, et al. Prediction of pre-eclampsia during early pregnancy in primiparas with soluble fms-like tyrosine kinase-1 and placental growth factor. Natl Med J India 2012;25: 68-73.
30. Vatten LJ, Eskild A, Nilsen TI, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007;196:239 e1-6.
31. Poon LC, Akolekar R, Lachmann R, et al. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 2010;35: 662-70.
32. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326 e1-13.
33. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818-24.
34. Crispi F, Llurba E, Dominguez C, et al. Predictive value of angiogenic factors and uterine artery Doppler for early-versus lateonset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31:303-9.
35. Mijal RS, Holzman CB, Rana S, et al. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med 2012;25:1135-41.
36. Straughen JK, Kumar P, Misra VK. The effect of maternal soluble FMS-like tyrosine kinase 1 during pregnancy on risk of preterm delivery. J Matern Fetal Neonatal Med 2012;25:1879-83.
37. Romero R, Chaiworapongsa T, Erez O, et al. An imbalance between angiogenic and anti-Angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med 2010;23:1384-99.
38. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-Angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
39. Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25-40.
40. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-Angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279-87.
41. Espinoza J, Romero R, Nien JK, et al. A role of the anti-Angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006;19:607-13.
42. Kusanovic JP, Romero R, Espinoza J, et al. Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol 2008;198:382 e1-8.
43. Su YN, Lee CN, Cheng WF, et al. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001;97:898-904.
44. Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-Angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24:1187-207.
45. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-Analysis. Br J Obstet Gynaecol 2012;119:778-87.
46. Sibai BM, Koch MA, Freire S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008;199: 268.e1-268.e9.
47. Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PlOS One 2010;5:e13263.1-12.
48. Dwyer BK, Krieg S, Balise R, et al. Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia. J Matern Fetal Neonatal Med 2010;23:705-11.
49. Verlohren S, Herraiz I, Lapaiare O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders an dits prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58.e1-8.
50. Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebocontrolled PREDO Trial and a meta-Analysis of randomised trials. BJOG 2013;120:64-74.
51. Group THSCR. Hyperglycemia and adverse pregnancy outcomes. New Engl J Med 2008;258:1991-2002.
52. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble Fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940-50.
53. Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59: 740-6.